Evidence map›Paper›PMID 39751876›Full record

ArticleArchives of toxicology2025

Critical comparison of BMD and TD

Robert Thomas, David J Ponting, Andrew Thresher, Joerg Schlingemann, John W Wills, George E Johnson

Abstract readComparative Study
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert ThomasLhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK.ORCID 0000-0003-0261-8720
David J PontingLhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK.ORCID 0000-0001-6840-2629
Andrew ThresherLhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK.ORCID 0000-0001-9470-1606
Joerg SchlingemannMerck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany. joerg.schlingemann@merckgroup.com.ORCID 0000-0003-4799-1086
John W WillsGlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, UK.ORCID 0000-0002-4347-5394
George E JohnsonInstitute of Life Science, Swansea University Medical School, Swansea, UK. g.johnson@swan.ac.uk.ORCID 0000-0001-5643-9942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumorigenic dose 50 (TD

Indexed as

CarcinogensNitrosaminesNitroso CompoundsAnimalsBenchmarkingDose-Response Relationship, DrugHumansModels, BiologicalRisk AssessmentCarcinogensNitrosaminesNitroso CompoundsAcceptable intakeBenchmark dose (BMD)Dose–response modelingDrug impuritiesNitrosaminesTD50

Identifiers

PMID39751876
PMCPMC11821704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.